French researcher reports successful drug trial for Coronavirus

PARIS: With early tests suggesting it can stop the virus from becoming contagious in just six days, A French researcher has reported successful trial of a new treatment line for Covid-19.

According to connexionfrance.com, Professor Didier Raoult from hospital l’Institut Hospitalo-Universitaire (IHU Mediterranee), put up a video to explain the trials held earlier this week.

Raoult, an infectious diseases specialist, was given task by the French government to research treatment for the novel coronavirus.
The first Covid-19 patients he treated with drug chloroquine saw rapid and effective speeding of their healing process, and a sharp decrease in the amount of time they remained contagious, according to the professor .

Chloroquine — which is normally used to prevent and treat malaria — was administered via drug Plaquenil.

Raoult quoted as saying by connexionfrance.com, that “We included everyone who was in agreement to be treated, which was almost everyone. Two towns in the protocol, Nice and Avignon, gave us infected patients who had not yet received treatment,”

In media report, the treatment was offered to 24 patients, who were among the first to become infected in the southeast of France, and who had voluntarily admitted themselves to hospital for the process. All Patients were given 600mcg per day for 10 days. They were closely monitored, as the drug can interact with other medication, and cause severe side effects in some cases.

He also added that, “We were able to ascertain that patients who had not received Plaquenil (drug containing hydroxychloroquine) were still contagious after six days, but of those who received Plaquenil, only 25 per cent were still contagious after the given period,”.

Chloroquine phosphate and hydroxychloroquine have previously been used to treat coronavirus patients in China, in ongoing Covid-19 clinical trials.

Kaletra, a US-based antiviral drug used to treat HIV, is another medicine that is being tested in the fight against the deadly virus.

  • Related Posts

    ‘Import of Refurbished Medical Devices’ Lobby has reared its Ugly Head

    Domestic Medical Device Leaders cry foul against move to do away with Policy Restrictions New Delhi:  The union government mandarins seem to be at it again, diametrically opposed to Prime…

    Indigenous Robotic Surgery is Mantra for Accessible Cancer Care in India

    Best in Class ‘Made in India’ Surgical Robot is proving Best Bet New Delhi: ‘Made in India’ best in class surgical robot SSiMantra is proving godsend for cancer patients in…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Medical Negligence and Quackery Rampant: 9-Year-Old Dies from Wrong Injection, Pregnant Woman Succumbs to Quack Treatment, Raids Uncover Illegal Practices Across MP, Haryana, UP & Chhattisgarh

    Medical Negligence and Quackery Rampant: 9-Year-Old Dies from Wrong Injection, Pregnant Woman Succumbs to Quack Treatment, Raids Uncover Illegal Practices Across MP, Haryana, UP & Chhattisgarh

    Drug Diversion Epidemic Sweeps India: Absence of Track-and-Trace System, overly Codeine Allotments, and Regulatory Apathy Fuel Misuse of Narcotic Syrups and Tablets

    Drug Diversion Epidemic Sweeps India: Absence of Track-and-Trace System, overly Codeine Allotments, and Regulatory Apathy Fuel Misuse of Narcotic Syrups and Tablets

    Multi-State Supply Chain of Fake RituxiRel and Alburel Injections Exposed Amid Health Risks

    Multi-State Supply Chain of Fake RituxiRel and Alburel Injections Exposed Amid Health Risks

    TN, Karnataka, Rajasthan declare highest number of NSQs in January

    TN, Karnataka, Rajasthan declare highest number of NSQs in January

    Centre reorganises CDSCO Zone Baddi amid Drug Quality Concerns

    Centre reorganises CDSCO Zone Baddi amid Drug Quality Concerns

    CDSCO modifies norms for testing permissions to speed up drug approvals

    CDSCO modifies norms for testing permissions to speed up drug approvals